Search Results - "PHILLIPS, Darren C"

5-Azacitidine Induces NOXA to Prime AML Cells for Venetoclax-Mediated Apoptosis by Jin, Sha, Cojocari, Dan, Purkal, Julie J, Popovic, Relja, Talaty, Nari N, Xiao, Yu, Solomon, Larry R, Boghaert, Erwin R, Leverson, Joel D, Phillips, Darren C

“…Patients with acute myeloid leukemia (AML) frequently do not respond to conventional therapies. Leukemic cell survival and treatment resistance have been…”
Get full text

Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models by Han, Lina, Zhang, Qi, Dail, Monique, Shi, Ce, Cavazos, Antonio, Ruvolo, Vivian R, Zhao, Yang, Kim, Eugene, Rahmani, Mohamed, Mak, Duncan H, Jin, Sha S, Chen, Jun, Phillips, Darren C, Koller, Paul Bottecelli, Jacamo, Rodrigo, Burks, Jared K, DiNardo, Courtney, Daver, Naval, Jabbour, Elias, Wang, Jing, Kantarjian, Hagop M, Andreeff, Michael, Grant, Steven, Leverson, Joel D, Sampath, Deepak, Konopleva, Marina

“…The pathogenesis of acute myeloid leukemia (AML) involves serial acquisition of mutations controlling several cellular processes, requiring combination…”
Get full text

MCL-1 Is a Key Determinant of Breast Cancer Cell Survival: Validation of MCL-1 Dependency Utilizing a Highly Selective Small Molecule Inhibitor by Xiao, Yu, Nimmer, Paul, Sheppard, George S, Bruncko, Milan, Hessler, Paul, Lu, Xin, Roberts-Rapp, Lisa, Pappano, William N, Elmore, Steven W, Souers, Andrew J, Leverson, Joel D, Phillips, Darren C

“…Hyperexpression of antiapoptotic BCL-2 family proteins allows cells to survive despite the receipt of signals that would ordinarily induce their deletion, a…”
Get full text

Pevonedistat and azacitidine upregulate NOXA (PMAIP1) to increase sensitivity to venetoclax in preclinical models of acute myeloid leukemia by Cojocari, Dan, Smith, Brianna N, Purkal, Julie J, Arrate, Maria P, Huska, Jason D, Xiao, Yu, Gorska, Agnieszka, Hogdal, Leah J, Ramsey, Haley E, Boghaert, Erwin R, Phillips, Darren C, Savona, Michael R

“…Dysregulation of apoptotic machinery is one mechanism by which acute myeloid leukemia (AML) acquires a clonal survival advantage. B-cell lymphoma protein-2…”
Get full text

MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma by Fu, Dechen, Pfannenstiel, Luke, Demelash, Abeba, Phoon, Yee Peng, Mayell, Cameron, Cabrera, Claudia, Liu, Caini, Zhao, Junjie, Dermawan, Josephine, Patil, Deepa, DeVecchio, Jennifer, Kalady, Matthew, Souers, Andrew J., Phillips, Darren C., Li, Xiaoxia, Gastman, Brian

“…Colorectal cancer (CRC) is one of the most common and deadliest forms of cancer. Myeloid Cell Leukemia 1 (MCL1), a pro-survival member of the Bcl-2 protein…”
Get full text

Aberrant reactive oxygen and nitrogen species generation in rheumatoid arthritis (RA): causes and consequences for immune function, cell survival, and therapeutic intervention by Phillips, Darren C, Dias, H K Irundika, Kitas, George D, Griffiths, Helen R

“…The infiltration and persistence of hematopoietic immune cells within the rheumatoid arthritis (RA) joint results in elevated levels of pro-inflammatory…”
Get more information

Free radicals and redox signalling in T-cells during chronic inflammation and ageing by Griffiths, Helen R, Dunston, Christopher R, Bennett, Stuart J, Grant, Melissa M, Phillips, Darren C, Kitas, George D

“…During chronic inflammation and ageing, the increase in oxidative stress in both intracellular and extracellular compartments is likely to influence local cell…”
Get more information

The anti‐inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species by Phillips, Darren C, Woollard, Kevin J, Griffiths, Helen R

“…The mechanism of action by which methotrexate (MTX) exerts its anti‐inflammatory and immunosuppressive effects remains unclear. The aim of this study is to…”
Get full text

Inhibition of cyclin‐dependent kinase 9 synergistically enhances venetoclax activity in mantle cell lymphoma by Zhao, Xiaoxian, Bodo, Juraj, Chen, Ruoying, Durkin, Lisa, Souers, Andrew J., Phillips, Darren C., Hsi, Eric D.

“…Mantle cell lymphoma (MCL) is an aggressive and largely incurable subtype of non‐Hodgkin's lymphoma. Venetoclax has demonstrated efficacy in MCL patients with…”
Get full text

Sphingosine-induced apoptosis in rhabdomyosarcoma cell lines is dependent on pre-mitochondrial Bax activation and post-mitochondrial caspases by Phillips, Darren C, Martin, Sophie, Doyle, Belinda T, Houghton, Janet A

“…Sphingolipids is the collective term ascribed to components of the sphingomyelin cycle. Modulation of the cellular levels of individual sphingolipids can…”
Get full text

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy by Leverson, Joel D, Phillips, Darren C, Mitten, Michael J, Boghaert, Erwin R, Diaz, Dolores, Tahir, Stephen K, Belmont, Lisa D, Nimmer, Paul, Xiao, Yu, Ma, Xiaoju Max, Lowes, Kym N, Kovar, Peter, Chen, Jun, Jin, Sha, Smith, Morey, Xue, John, Zhang, Haichao, Oleksijew, Anatol, Magoc, Terrance J, Vaidya, Kedar S, Albert, Daniel H, Tarrant, Jacqueline M, La, Nghi, Wang, Le, Tao, Zhi-Fu, Wendt, Michael D, Sampath, Deepak, Rosenberg, Saul H, Tse, Chris, Huang, David C S, Fairbrother, Wayne J, Elmore, Steven W, Souers, Andrew J

“…The BCL-2/BCL-XL/BCL-W inhibitor ABT-263 (navitoclax) has shown promising clinical activity in lymphoid malignancies such as chronic lymphocytic leukemia…”
Get more information

A novel CDK9 inhibitor increases the efficacy of venetoclax (ABT-199) in multiple models of hematologic malignancies by Phillips, Darren C., Jin, Sha, Gregory, Gareth P., Zhang, Qi, Xue, John, Zhao, Xiaoxian, Chen, Jun, Tong, Yunsong, Zhang, Haichao, Smith, Morey, Tahir, Stephen K., Clark, Rick F., Penning, Thomas D., Devlin, Jennifer R., Shortt, Jake, Hsi, Eric D., Albert, Daniel H., Konopleva, Marina, Johnstone, Ricky W., Leverson, Joel D., Souers, Andrew J.

“…MCL-1 is one of the most frequently amplified genes in cancer, facilitating tumor initiation and maintenance and enabling resistance to anti-tumorigenic agents…”
Get full text

Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors by Phillips, Darren C, Buchanan, Fritz G, Cheng, Dong, Solomon, Larry R, Xiao, Yu, Xue, John, Tahir, Stephen K, Smith, Morey L, Zhang, Haichao, Widomski, Deborah, Abraham, Vivek C, Xu, Nan, Liu, Zhihong, Zhou, Li, DiGiammarino, Enrico, Lu, Xin, Rudra-Ganguly, Nandini, Trela, Bruce, Morgan-Lappe, Susan E

“…TRAIL can activate cell surface death receptors, resulting in potent tumor cell death via induction of the extrinsic apoptosis pathway. Eftozanermin alfa…”
Get full text

Structure-Guided Design of a Series of MCL‑1 Inhibitors with High Affinity and Selectivity by Bruncko, Milan, Wang, Le, Sheppard, George S, Phillips, Darren C, Tahir, Stephen K, Xue, John, Erickson, Scott, Fidanze, Steve, Fry, Elizabeth, Hasvold, Lisa, Jenkins, Gary J, Jin, Sha, Judge, Russell A, Kovar, Peter J, Madar, David, Nimmer, Paul, Park, Chang, Petros, Andrew M, Rosenberg, Saul H, Smith, Morey L, Song, Xiaohong, Sun, Chaohong, Tao, Zhi-Fu, Wang, Xilu, Xiao, Yu, Zhang, Haichao, Tse, Chris, Leverson, Joel D, Elmore, Steven W, Souers, Andrew J

“…Myeloid cell leukemia 1 (MCL-1) is a BCL-2 family protein that has been implicated in the progression and survival of multiple tumor types. Herein we report a…”
Get full text

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia by Tahir, Stephen K., Calvo, Emiliano, Carneiro, Benedito A., Yuda, Junichiro, Shreenivas, Aditya, Jongen-Lavrencic, Mojca, Gort, Eelke, Ishizawa, Kenichi, Morillo, Daniel, Biesdorf, Carla, Smith, Morey, Cheng, Dong, Motwani, Monica, Sharon, David, Uziel, Tamar, Modi, Dimple A., Buchanan, Fritz G., Morgan-Lappe, Susan, Medeiros, Bruno C., Phillips, Darren C.

“…•The antitumorigenic activity of eftoza is enhanced in combination with venetoclax in preclinical models of AML.•Eftoza-venetoclax combination is well…”
Get full text

Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia by Cathelin, Severine, Sharon, David, Subedi, Amit, Cojocari, Dan, Phillips, Darren C., Leverson, Joel D., MacBeth, Kyle J., Nicolay, Brandon, Narayanaswamy, Rohini, Ronseaux, Sebastien, Liu, Guowen, Chan, Steven M.

Get full text

Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells by Bodo, Juraj, Zhao, Xiaoxian, Durkin, Lisa, Souers, Andrew J, Phillips, Darren C, Smith, Mitchell R, Hsi, Eric D

“…The chromosomal translocation t(14;18) in follicular lymphoma (FL) is a primary oncogenic event resulting in BCL-2 over-expression. This study investigates…”
Get full text

Discovery of a Potent and Selective BCL‑XL Inhibitor with in Vivo Activity by Tao, Zhi-Fu, Hasvold, Lisa, Wang, Le, Wang, Xilu, Petros, Andrew M, Park, Chang H, Boghaert, Erwin R, Catron, Nathaniel D, Chen, Jun, Colman, Peter M, Czabotar, Peter E, Deshayes, Kurt, Fairbrother, Wayne J, Flygare, John A, Hymowitz, Sarah G, Jin, Sha, Judge, Russell A, Koehler, Michael F. T, Kovar, Peter J, Lessene, Guillaume, Mitten, Michael J, Ndubaku, Chudi O, Nimmer, Paul, Purkey, Hans E, Oleksijew, Anatol, Phillips, Darren C, Sleebs, Brad E, Smith, Brian J, Smith, Morey L, Tahir, Stephen K, Watson, Keith G, Xiao, Yu, Xue, John, Zhang, Haichao, Zobel, Kerry, Rosenberg, Saul H, Tse, Chris, Leverson, Joel D, Elmore, Steven W, Souers, Andrew J

“…A-1155463, a highly potent and selective BCL-XL inhibitor, was discovered through nuclear magnetic resonance (NMR) fragment screening and structure-based…”
Get full text

Expanding the Repertoire for "Large Small Molecules": Prodrug ABBV-167 Efficiently Converts to Venetoclax with Reduced Food Effect in Healthy Volunteers by Salem, Ahmed Hamed, Tao, Zhi-Fu, Bueno, Orlando F, Chen, Jie, Chen, Shuang, Edalji, Rohinton, Elmore, Steven W, Fournier, Keith M, Harper, Kaid C, Hong, Richard, Jenkins, Gary J, Ji, Jianguo, Judge, Russell A, Kalvass, John C, Klix, Russell C, Ku, Yi-Yin, Leverson, Joel D, Marks, Richard A, Marsh, Kennan C, Menon, Rajeev M, Park, Chang H, Phillips, Darren C, Pu, Yu-Ming, Rosenberg, Saul H, Sanzgiri, Yeshwant D, Sheikh, Ahmad Y, Shi, Yi, Stolarik, Deanne, Suleiman, Ahmed A, Wang, Xilu, Zhang, Geoff G Z, Catron, Nathaniel D, Souers, Andrew J

“…Since gaining approval for the treatment of chronic lymphocytic leukemia (CLL), the BCL-2 inhibitor venetoclax has transformed the treatment of this and other…”
Get full text

Structure-Based Design of A-1293102, a Potent and Selective BCL-X L Inhibitor by Tao, Zhi-Fu, Wang, Xilu, Chen, Jun, Ingram, Justin P, Jin, Sha, Judge, Russell A, Kovar, Peter J, Park, Chang, Sun, Chaohong, Wakefield, Brian D, Zhou, Li, Zhang, Haichao, Elmore, Steven W, Phillips, Darren C, Judd, Andrew S, Leverson, Joel D, Souers, Andrew J

“…BCL-X , an antiapoptotic member of the BCL-2 family of proteins, drives tumor survival and maintenance and thus represents a key target for cancer treatment…”
Get full text